REVELATION BIOSCIENCES INC (REVB)
US76135L5075 - Common Stock
Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements.
Wondering how the US markets performed one hour before the close of the markets on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis.
Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes.
Let's have a look at the top gainers and losers in the middle of the day of today's session.
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Tuesday.
Let's have a look at the gap up and gap down stocks in today's session.
Revelation Biosciences Inc. Announces Exercise of Warrants for $4 Million in Gross Proceeds
Monday's after hours session: top gainers and losers
Let's have a look at what is happening on the US markets after the closing bell on Monday. Below you can find the top gainers and losers in today's after hours session.
Revelation Biosciences Inc. Announces FDA Acceptance of Gemini IND
Revelation Biosciences, Inc. Completes the GMP Manufacture of Gemini Clinical Drug Supply
Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2024
Revelation Biosciences’ Gemini Induces Dose Dependent Significant Increases in IL-10
Revelation Biosciences Inc. Announces Exercise of Warrants for $3.8 Million in Gross Proceeds
REVB Stock Earnings: Revelation Biosciences Misses EPS for Q2 2024
REVB stock results show that Revelation Biosciences missed analyst estimates for earnings per share the second quarter of 2024.
REVB Stock Earnings: Revelation Biosciences Misses EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Revelation Biosciences (NASDAQ:REVB) just reported results for the second quart...
Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2024
Revelation Biosciences Announces Phase 1 Clinical Study of Gemini Met the Primary Safety Endpoint and Showed Statistically Significant Biomarker Activity
Revelation Biosciences Has Completed Dosing of its First in Human Phase 1 Clinical Study of Gemini
REVB Stock Earnings: Revelation Biosciences Misses EPS for Q1 2024
REVB stock results show that Revelation Biosciences missed analyst estimates for earnings per share the first quarter of 2024.
REVB Stock Earnings: Revelation Biosciences Misses EPS for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Revelation Biosciences (NASDAQ:REVB) just reported results for the first quarte...
Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2024
REVB Stock Earnings: Revelation Biosciences Beats EPS for Q4 2023
REVB stock results show that Revelation Biosciences beat analyst estimates for earnings per share the fourth quarter of 2023.
REVB Stock Earnings: Revelation Biosciences Beats EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Revelation Biosciences (NASDAQ:REVB) just reported results for the fourth quart...
Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2023
Revelation Biosciences Inc. Gives Oral Presentation at Advances in Critical Care Nephrology (AKI & CRRT 2024)
Revelation Biosciences Inc. to Participate in a Virtual Fireside Chat at the 36th Annual Roth Conference
Revelation Biosciences Inc. Announces Commencement of First in Human Phase 1 Clinical Study of Gemini
Revelation Biosciences Inc. Receives Invitation to Give an Oral Presentation at The 29th International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024)
